2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over $3B in deals from Lilly, GSK, and others, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. That’s why this year’s Antifibrotic […]

With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, regulatory change is accelerating, solidifying Model-Informed Drug Development (MIDD) as a critical, non-negotiable tool in the drug development process. The Model-Informed Drug Development Summit is the first and only industry-focused, 3-day strategic meeting dedicated to exploring how MIDD is […]

3rd LNP Characterization & Analytical Development Summit De-Risk Regulatory Submissions Through Smarter LNP Characterization Curated in collaboration with leading analytical scientists and key LNP stakeholders, the 3rd LNP Characterization & Analytical Development Summit returns with new data, fresh insights, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization, this summit […]

The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond... Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells, this forum dives into myeloid reprogramming, cell state heterogeneity, and translational […]

The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research, and clinical pipelines facing intensifying competition, the need to develop differentiated, […]

Returning for its third year, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell sourcing for allogeneic therapies. This summit brings together leading minds from biopharma, blood banks, apheresis providers, and cell therapy innovators to address one of the […]

Diving Into the Complement Cascade to Explore Intervention Points, Harnessing Biomarker Strategies to Identify Optimal Patient Populations, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. So far, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis, Annexon Biosciences and Omeros, are making […]

Recognized as the industry’s leading forum for cell therapy analytical, quality control, assay, and CMC professionals, the 7th Cell Therapy Analytical Development Summit, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda, Arsenal Bio, Bayer, Genentech, Adicet Bio, Quell Therapeutics, and […]

RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field has seen major collaborations, including Wayfinder Biosciences with Daiichi Sankyo, Ono Pharmaceutical with Reborna Biosciences, […]

The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. Don't miss this pivotal opportunity […]

With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes, new FDA draft guidance on post-approval CMC, and potency assays facing heightened scrutiny, the environment is rapidly evolving. Global efforts to align […]

The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences Most roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself, in what jobs, with what skills, and across what proportion of our workforces is not yet fully clear. What is clear, […]

Navigate New FDA Leadership, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell […]

The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore […]

Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from strength to strength. With a surge of billion-dollar investments, the release of new groundbreaking data, and recent real-world clinical progression, the autoimmune cell therapy field is […]

With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions, there has never been a more important year to stay up to […]

As biopharma organizations decrease their budgets and move away from a recruitment-centric approach, the need to develop existing talent to fill key technical skills gaps has never been more mission critical. This December in Boston, LEAP TD: Life Sciences will bring together senior talent development leaders from across biopharma to explore how learning and development can directly support […]

With the launch of the FDA’s Project Optimus, and the evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. Bringing together a focused audience of clinical pharmacology, PK, pharmacometrics, modelling, and bioanalysis specialists, the 2nd ADC Pharmacokinetics & Clinical Pharmacology […]

Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving robust amyloid clearance, challenges remain in reaching targeted brain regions, improving predictive modelling, ensuring efficacy and penetrance, and developing safer, targeted delivery approaches. Join 100+ […]

The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent - or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex, strategic acquisitions from Eli Lilly, and late-stage successes validating the commercial potential of novel mechanisms. However, the clinical pathway […]

With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects continue to limit therapeutic success, highlighting the critical need for optimized delivery approaches. Recent developments, including Genentech’s Susvimo label expansion, advances in sustained-release and suprachoroidal delivery […]

2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. […]

Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting […]

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 - 29 January 2026, this essential meeting unites 170+ senior leaders across R&D, CMC (Chemistry, Manufacturing, and Controls), Regulatory […]

The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. Over three days, the summit brings together senior decision-makers from biopharma, biotech innovators, investors, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. As the aging population grows, […]

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling. As the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies, the oncology landscape is transforming. Exciting modalities like ADCs, bispecifics, T-cell engagers demand smarter, more predictive […]

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the urgency for more effective, disease-modifying interventions has never been greater. In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting the field in San Diego February 3-5, 2026 for 3 days of data- and strategy-driven presentations and networking sessions, the 10th Liquid Biopsy for Precision […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable. Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event […]

The Longest Standing & Pre-Eminent European ADC Forum 16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers With traditional ADCs now fulfilling their potential to reshape oncology care, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. Returning as the longest-standing […]